Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 10/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | PAICS | P22234 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16722069 | 0.92 | BRD4 (0.59) | BRD4TGFBR1CREBBPFGFR1FLT3 | |
| SCHEMBL16722067 | 0.92 | BRD4 (0.59) | BRD4TGFBR1CREBBPFGFR1FLT3 | |
| SCHEMBL17018118 | 0.91 | BRD4 (0.52) | BRD4NAMPTCREBBP | |
| SCHEMBL17018264 | 0.91 | BRD4 (0.53) | BRD4TGFBR1NAMPTCREBBPFLT3 | |
| SCHEMBL17018117 | 0.90 | BRD4 (0.51) | BRD4TGFBR1NAMPTTTK | |
| SCHEMBL17018266 | 0.88 | BRD4 (0.49) | BRD4NAMPT | |
| SCHEMBL17018115 | 0.88 | BRD4 (0.49) | BRD4FLT3 | |
| SCHEMBL17018112 | 0.88 | BRD4 (0.55) | BRD4NAMPTCREBBP | |
| SCHEMBL16722066 | 0.87 | BRD4 (0.51) | BRD4NAMPTCREBBP | |
| SCHEMBL17018120 | 0.86 | BRD4 (0.51) | BRD4NAMPTTTKCREBBPFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2016-09-08 | — | — | US | disclosed |
| US-9422281-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | FORMA THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20150232465-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | FORMA THERAPEUTICS, INC. | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232465-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885TGFBR1 1868/4885NAMPT 2915/4885 |
| US-20160256458-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885TGFBR1 1868/4885NAMPT 2915/4885 |
| US-10377769-B2 | Benzopiperazine compositions as BET bromodomain inhibitors | BRD4, BRPF3, BRD7 | BRD4 1/4885TGFBR1 1868/4885NAMPT 2915/4885 |
| US-20160257699-A1 | BENZOPIPERAZINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS | BRD4, BRPF3, BRD7 | BRD4 1/4885TGFBR1 1868/4885NAMPT 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.